Overview of Development Pipeline

CHUGAI PHARMACEUTICAL CO., LTD.
Senior Vice President
Head of Lifecycle Management Marketing Unit
Tatsuro Kosaka

July 23/24, 2009

Projects under Development (as of July 23, 2009)

	Phase I	Phase II	Phase III	Filed
Oncology	**TP300 - CRC** **CIF/R7167 - solid tumor** **CKI27/R7304** **- solid tumor** **GC33 - liver cancer** R7159/GA101 - NHL R1507(hIGF-1R) - solid tumor	**MRA/Actemra - MM** R435/Avastin - BC R1415/Tarceva - PC	**EPOCH/Epogin - CIA** R340/Xeloda - GC R435/Avastin - aCC - GC - aBC - Glioblastoma★ R597/Herceptin - GC R1273/pertuzumab - BC	R340/Xeloda - CRC R435/Avastin - NSCLC
Bone & Joint		**MRA/Actemra - RA(sc)** R484/Bonviva(oral) - osteoporosis	**MRA/Actemra (overseas)** **- sJIA** **ED-71 - osteoporosis** R1594/ocrelizumab - RA R484/Bonviva(inj) - osteoporosis	**MRA/Actemra – RA (US)**
Renal				R744/Mircera - renal anemia★
Others	**NA808 - HCV** **MRA/Actemra (overseas)** **- Castleman's disease** **MRA/Actemra - SLE** R1579/(DPPIV) - diabetes	**CSG452/R7201** **- diabetes** **GM-611 - gastroparesis** **MRA/Actemra** **- Crohn's disease** R1583(GLP-1) - diabetes★ R1678/(GlyT-1) - schizophrenia	R442/Pegasys - HBV R442+R964/Pegasys + Copegus - cirrhosis	**EPOCH/Epogin** **- autologous blood transfusion**

Letters in purple: in-house projects
★Projects with advances in stages since Apr 24, 2009

Development Status – Oncology (1)

In-house

Epogin (epoetin beta)

Chemotherapy-induced anemia: primary endpoint achieved in phase 3 trial

- ➡ Theoretical transfusion rate significantly reduced
- ➡ Plan to file for approval with the phase 3 data by end of 2009

In-house

TP300 (topoisomerase I inhibitor)

Solid tumor: phase 1 status overseas, phase 1 data presented at ASCO

Development Status – Oncology (2)

Roche Product

Avastin (bevacizumab)

Non-small cell lung cancer: filed in November 2008, review on-going

- Filed with domestic phase 2 data & overseas phase 3 data
- Designated for a priority review

Breast cancer: plan to file by end of 2009

- To be filed with with domestic phase 2 data & overseas phase 3 data

Adjuvant colon cancer: global AVANT study on-going

- US C-08 study did not meet the primary endpoint
- Results expected in 2010 for AVANT study

Glioblastoma: decided to join the global phase 3 study

- First patient dosing expected by end of 2009 in Japan

Development Status – Oncology (3)

Roche Product

Tarceva (erlotinib)

Pancreatic cancer: To be filed by end of 2009 with domestic phase 2 data & overseas phase 3 data

Roche Product

Herceptin (trastuzumab)

Gastric cancer: positive results from ToGA study

- ToGA results presented at ASCO (primary endpoint achieved)
- Plan to file for approval in 2010

Roche Product

Xeloda (capecitabine)

Colorectal cancer: filed in February 2008, review on-going

Gastric cancer: comadministered in ToGA and AVAGAST studies

- Combination with Herceptin (ToGA) or Avastin (AVAGAST)
- Plan to file in 2010 and 2011, with above studies

Development Status – Bone & Joints

In-house

Actemra (tocilizumab)

Rheumatoid Arthritis: Good results also for 2 year analysis of LITHE

- 2 year data of LITHE demonstrated continued inhibition of structural joint damage and high remission rate observed in 1 year analysis
- Data presented at EULAR
  - Long term extension studies, GROWTH95&96 data demonstrates up to 56% remission in more than 2 years treatment, regardless of previous treatment or duration of disease
  - 1 year data from LITHE demonstrates inhibition of structural joint damage and high remission rate

In-house

ED-71 (eldecalcitol)

Active Vitamin D3 Derivative; co-development with Taisho Pharmaceutical

Osteoporosis: To be file by end of 2009 with positive phase 3 data

- Significantly reduced the incidence of new vertebral fractures

Development Status – Renal & Others

Roche Product

C.E.R.A. (continuous erythropoetin receptor activator)

Renal anemia: Filed in July 2009

- Filed for anemia in hemo-dialysis, peritoneal-dialysis and pre-dialysis patients, utilizing data from six domestic phase 3 studies

Roche Product

R1583/ITM-077 (taspoglutide)

GLP-1 analogue; co-development with Teijin

Type II diabetes: started domestic phase 2 study

Roche Product

Tamiflu Dry Syrup 3%

Anti-influenza virus: partial amendment approved in July 2009

- Shelf-life extended to three years from previous two years; change in site of manufacturing

Projected Submissions



Contacts:

Corporate Communications Group

Tel: +81 (0)3-3273-0881 Fax: +81 (0)3-3281-6607
e-mail: pr@chugai-pharm.co.jp

Masayuki Yamada, Seiji Shimada, Hiroshi Araki

Investor Relations Group

Tel: +81 (0)3-3273-0554 Fax: +81 (0)3-3281-6607
e-mail: ir@chugai-pharm.co.jp

Mac Uchida, Kae Maeda, Tomoko Shimizu, Yusuke Tokita